RxDoctor Payments DataLook up a doctor →

Sara Dhanani, MD

Neurology · Sun City, AZNPI 1063614873

Payments from drug & device makers

$1,369,045in general payments, 2019–2025

Across 305 payments — averaging $4488.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.2M
  • Sage Therapeutics, LLC$132K
  • Bayer$2K
  • Boston Scientific$1K
  • Medtronic$1K
  • Amneal Pharmaceuticals LLC$812
  • plus $1K from 14 others
$1,147in research payments, 2019–2025

Across 17 payments — averaging $67.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Consulting fees$9,25047%
  • Speaking & faculty fees$7114%
  • Travel & lodging$4,66324%
  • Food & beverage$4,90525%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,369,045 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$181,286
Medicare patients
209
Services billed
17,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate31$248,036
NuplazidPimavanserin Tartrate30$183,226
GocovriAmantadine Hcl56$148,192
RytaryCarbidopa/Levodopa118$118,468
NuedextaDextromethorphan Hbr/Quinidine12$17,116
Carbidopa-Levodopa ErCarbidopa/Levodopa203$15,945
Carbidopa-LevodopaCarbidopa/Levodopa287$10,423
Rasagiline Mesylate46$7,386
AmantadineAmantadine Hcl129$5,974
Rivastigmine25$3,761
Primidone105$3,079
Entacapone16$2,789
Clonazepam118$2,203
Ropinirole Hcl91$2,017
Escitalopram Oxalate94$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$144$248,03631 claims
Acadia Pharmaceuticals IncNuplazid$277$183,22630 claims
MDD US Operations, LLCGocovri$192$148,19256 claims
Amneal Pharmaceuticals LLCRytary$812$118,468118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.

Other neurology in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →